Q-omics provides the consensus-scored SELENOWP1 profile across patient tissues and cancer cell-line models. SELENOWP1 expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, SELENOWP1 is differentially expressed in 4, with the highest sampling consensus in COAD. Additionally, SELENOWP1 RNA expression shows 6,454 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight KIRP, COAD, and STAD as cancer lineages where SELENOWP1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SELENOWP1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SELENOWP1 survival associations across molecular data types. SELENOWP1 RNA expression shows survival associations in the most cancer types (17). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SELENOWP1 RNA expression–survival associations across cancer types. High SELENOWP1 expression shows unfavorable associations in THYM and HNSC, but favorable associations in KIRP, UCEC, KIRC and KICH. The KIRP Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .004). Together, the overview and detailed table identify KIRP as the clearest survival context for SELENOWP1 RNA expression.
This table summarizes SELENOWP1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for SELENOWP1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SELENOWP1 shows lower tumor expression in PAAD and LUSC and higher tumor expression in COAD and LIHC. The COAD box plot shows higher SELENOWP1 RNA expression in tumor versus normal tissue (log2 FC = +1.027, t-test p < 0.001).
This table shows molecular features associated with SELENOWP1 in patient tissues and cancer cell lines. In patient samples, SELENOWP1 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
